Pluristem in academic partnership to test cell therapy
Israel-based Pluristem Therapeutics Inc has entered into a long-term collaboration with the Hadassah Medical Center in Jerusalem to assess the potential efficacy of a cell therapy for the treatment of complications arising from bone marrow transplantations.
Israel-based Pluristem Therapeutics Inc has entered into a long-term collaboration with the Hadassah Medical Center in Jerusalem to assess the potential efficacy of a cell therapy for the treatment of complications arising from bone marrow transplantations.
The university’s medical center will use preclinical models to evaluate the potential of the company’s allogeneic cell therapy which is derived from full-term human placentas. The cells are expanded in bioreactor systems and grown in a fully automated operation. The cells are understood to release therapeutic proteins in response to inflammation, haematological disorders, radiation damage and ischaemia.
The product in question is intended for the treatment and prevention of haematological deficiencies and complications of bone marrow and umbilical cord blood transplantation. Called PLX-RAD, it is Pluristem’s second cell therapy product candidate. The company also has a clinical-stage cell therapy programme for the treatment of multiple cardiovascular and orthopaedic indications.
Pluristem announced the collaboration on 4 December 2014.
Copyright 2014 Evernow Publishing Ltd